Bolt Biotherapeutics is a clinical-stage biotech company working to harness the power of the immune system to improve lives and eradicate cancer. The company is developing novel immunotherapies using an approach that uses foreign patterns to trigger the innate immune system, which then teaches the immune system to recognize and kill cancer.

Bolt was founded in 2015 by Dr. Edgar G. Engleman of Stanford University to expand upon his pioneering work in cancer immunotherapeutics and myeloid biology. Bolt is based in the San Francisco Bay area.

The Company’s highly qualified management team includes experienced leaders in immuno-oncology drug discovery, development, and commercialization. We are applying our expertise to the discovery and development of transformative treatments to address key unmet medical needs for patients with cancer.